SAN DIEGO, Jan. 13 /PRNewswire/ -- NexBio, a privately held development-stage biopharmaceutical company located in San Diego, announced today that David Wurtman, MD, MBA, Vice President of Corporate Development, will present a corporate overview at the upcoming 2009 Biotech Showcase in San Francisco, CA, on January 14, 2009 at 2:15pm. NexBio's corporate mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases.
NexBio's pipeline consists of two novel biopharmaceuticals invented internally, DAS181 (Fludase(R)), in clinical development, and Viradin(TM), at lead optimization stage, as well as TOSAP(TM), an important new microparticle formulation technology. Corporate funding to date has been entirely non-dilutive, consisting of five grants totaling $13M, together with a BAA Contract for $49.8M to support Fludase(R) development, all from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Fludase(R) is a broad-spectrum drug candidate for the prophylaxis and treatment of respiratory infections by all variations of influenza virus, including the types of virus that may cause a potential influenza pandemic. In addition, Fludase(R) has the potential for prophylaxis and treatment of seasonal influenza-like illness due to multiple respiratory viruses, including parainfluenza virus, which may cause a serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic. Fludase(R) is a recombinant fusion protein that inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza and parainfluenza viruses both from infecting the human body and from amplifying in already-infected individuals. Fludase(R) effectively inhibits numerous strains of influenza and parainfluenza virus nonclinical models. Unlike current antiviral compounds and vaccines, Fludase(R) targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with currently available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance.
Viradin(TM) is a highly-stable protein, currently at lead optimization stage, directed to the treatment of viral hemorrhagic fever caused by viruses such as Ebola and Marburg, as well as the treatment of sepsis and septic shock. TOSAP(TM) is a novel, elegant, inexpensive & easily scalable microparticle formulation technology invented and developed by NexBio, used to formulate Fludase for inhalation as well as the compounds of partners, under license. NexBio has recently begun a collaboration with a Pharma company to formulate one of their proprietary antibodies. TOSAP has been shown to successfully formulate multiple classes of molecule, such as protein (including peptides and antibodies), small molecule, oligonucleotides (including siRNA) and virus.
For more information about NexBio, Inc., please visit http://www.nexbio.com
Contact: David Wurtman, M.D., M.B.A VP, Corporate Development 10665 Sorrento Valley Road San Diego, CA 92121 Phone: (858) 452-2631 email@example.com
Note: FDA has yet to approve the name Fludase.
This release contains forward-looking information about the research and development program of NexBio and the potential efficacy of product candidates that might result from programs that involve substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to permit the clinical investigation of or approve any drug applications that may result from the programs as well as their decisions regarding labeling and other matters that could affect the commercial potential of product candidates that may result from the program; and competitive developments.
Copyright©2009 PR Newswire.
All rights reserved